Governance of the Directorate of Drug Administration: Challenges and Way forward
About the chapter:
Transparency International Bangladesh (TI-B) is an independent, non-government, non-partisan and non-profit organization with a vision of Bangladesh in which government, politics, business, civil society and the daily lives of the people shall be free from corruption.
CPI Score: 26
CPI Rank: 149
View chapter Profile
Theory of Change
Policy & Insititutional ChangeImproved enforcement of policies Better Institutional Processes
The study by TI-Bangladesh has assessed the effectiveness of the Government Drug Administration to tackle corruption.
The study follows recent measures by the Government to strengthen the capacities of the Drug Administration. These include an increase of work force in field offices and measures to construct central drug laboratory and its capacity building. Moreover, it has taken measures to implement directives given by the Parliamentary Standing Committee on Health to strengthen its operations to prevent flourish of fake and adulterated drugs, formation of an Ethics Committee as per the National Integrity Strategy 2013 and formation of an Innovation Team for bringing visible changes in its client service delivery.
It is a qualitative study. Information has been collected and analysed from both primary and secondary sources.
The methods applied to collect information from primary sources includes: key informant interviews; group discussions; case studies and; observations.
Primary sources of information were current and former officials of the Drug Administration (from central and local offices), members of different committees associated with the Drug Administration DA, owners and officials of different companies, proprietors of retail drug stores, police officials, medical practitioners and experts and researchers on the drug sector.
Secondary sources were existing laws and rules, official documents, websites, research reports and articles and news published in different newspapers. The study has been conducted March 2014 - January 2015
- The institutional capacity of the Drug Administration is not adequate considering the scope, geographic coverage and expansion of drug market. There are institutional limitations in terms of human resources, infrastructure, logistics and skills for operating its activities properly.
- The legal structure is not sufficiently strong for monitoring and controlling the drug market and for facing contemporary challenges.
- Lack of proper implementation of the law and a lack of transparency and accountability in terms of operating the mandate of the Drug Administration.
- Lack of political will in strengthening the capacity of the Drug Administration at the policy making level is evident.
- The pharmaceutical companies producing sub-standard, fake and adulterated drugs should be identified and legal actions should be made against them.
- Representation of the pharmaceutical owners in different drug related committees (especially drug control committee, manufacturing license committee, drug-pricing committee, and block list approval committee) should be avoided.
- At least one position of drug inspector should be created in each district offices considering the market size and workload.
- Drug administration infrastructure should be set up in every district and logistical support and transport facilities for inspection should be ensured.